🇺🇸 FDA
Patent

US 6528661

Hydrolysis of [R(R*,R*)]-2-(4-fluorophenyl)-&bgr;,&dgr;-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide

expired A61KA61K9/282A61K9/5021

Quick answer

US patent 6528661 (Hydrolysis of [R(R*,R*)]-2-(4-fluorophenyl)-&bgr;,&dgr;-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide) held by TEVA PHARMACEUTICAL INDUSTRIES, LTD. expires Mon Feb 27 2023 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
TEVA PHARMACEUTICAL INDUSTRIES, LTD.
Grant date
Tue Mar 04 2003 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 27 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K9/282, A61K9/5021